Results 31 to 40 of about 3,750,451 (195)

Novel agents for anti-platelet therapy

Journal of Hematology & Oncology, 2011
Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most commonly used anti-platelet drugs, namely, aspirin, ticlopidine, and clopidogrel, are effective in the prevention and treatment of cardio ...
Ji Xuebin, Hou Ming
doaj   +1 more source

Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2015
Patients with diabetes mellitus (DM) have accelerated atherosclerosis with an increased risk for atherothrombotic cardiovascular complications. A state of high platelet reactivity and activation, hypercoagulability (prothrombotic state) and a subdued ...
Jung Hwa Jung, Udaya S. Tantry, Paul A. Gurbel, Young-Hoon Jeong   +3 more
doaj   +1 more source

Bleeding complications following peripheral regional anaesthesia in patients treated with anticoagulants or antiplatelet agents: A systematic review.

Anaesthesia Critical Care & Pain Medicine, 2019
BACKGROUND Patients on either antiplatelet or anticoagulant therapy may need procedures performed under peripheral nerve blocks in preference to general anaesthesia techniques.
F. Joubert, P. Gillois, H. Bouaziz, E. Marret, G. Iohom, P. Albaladéjo   +5 more
semanticscholar   +1 more source

Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.

Pharmacology and Therapeutics, 2019
Antiplatelet drugs serve as a first-line antithrombotic therapy for the management of acute ischemic events and the prevention of secondary complications in vascular diseases.
Q. Xiang, Xiaocong Pang, Zhenming Liu, Guoping Yang, Weikang Tao, Qi Pei, Yi-min Cui   +6 more
semanticscholar   +1 more source

Pharmacogenetics of Antiplatelet Drugs

The Scientific World Journal, 2002
Pharmacogenetics refers to the genetic factors that influence the response to a drug, often involving genetic variations in drug metabolizing enzymes. The pharmacogenetics of antiplatelet agents is in its infancy and largely reflects variations in drug ...
Ronan Curtin, Desmond J. Fitzgerald
doaj   +1 more source

Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study

Journal of Clinical Medicine, 2019
While evidence is accumulating that platelets contribute to tissue destruction in tuberculosis (TB) disease, it is still not known whether antiplatelet agents are beneficial to TB patients.
Meng-Rui Lee, Ming-Chia Lee, Chia-Hao Chang, Chia-Jung Liu, Lih-Yu Chang, Jun-fu Zhang, Jann-Yuan Wang, C. Lee   +7 more
semanticscholar   +1 more source

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents

Molecules, 2023
Antiplatelet aggregation agents have demonstrated clinical benefits in the treatment of ischemic stroke. In our study, a series of novel nitric oxide (NO)-donating ligustrazine derivatives were designed and synthesized as antiplatelet aggregation agents.
Han-Xu Li, Jian-Hui Tian, Hua-Yu Li, Xin Wan, Yu Zou   +4 more
doaj   +1 more source

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation.

American Journal of Medicine, 2019
PURPOSE Patients with nonvalvular atrial fibrillation commonly have comorbidities requiring concurrent use of oral anticoagulants and antiplatelets. There are no real-world data on the comparative safety of concomitant antithrombotic treatments in the ...
A. Douros, C. Renoux, H. Yin, K. Filion, S. Suissa, L. Azoulay   +5 more
semanticscholar   +1 more source

Effects of Antiplatelet Agents on Functional Outcome and Cognitive Status in Patients with Acute Ischemic Stroke

International Journal of Gerontology, 2014
Background: The effect of antiplatelet agents for the treatment of acute stroke is less certain than that for the treatment of acute myocardial ischemia.
Yong Zhang, Zhenxin Zhang, Baiyu Yang, Yanfeng Li, Qi Zhang, Qiumin Qu, Yanping Wang, Shihong Zhang, Weidong Yue, Yuhui Tan, Baorong Zhang, Jingjing Liang   +11 more
doaj   +1 more source

Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches

Frontiers in Cardiovascular Medicine, 2022
Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral ...
Georges Jourdi, Georges Jourdi, Anne Godier, Anne Godier, Marie Lordkipanidzé, Marie Lordkipanidzé, Guillaume Marquis-Gravel, Guillaume Marquis-Gravel, Pascale Gaussem, Pascale Gaussem   +9 more
doaj   +1 more source